JF Tremblay's Anti-Aging Stack

Epithalon at 3.3-5mg daily for 20-30 days (100mg total per cycle), repeated 2-3 times per year. This is longer than the standard 5-10 day Khavinson pulse. BPC-157 runs in two modes: either 250mcg daily for 2 weeks on, 6 weeks off, or a single 10mg high-dose pulse once monthly. The dual-dose BPC-157 approach gives you a choice between steady low-dose repair and periodic high-dose bursts. Tremblay owns CanLab, a peptide manufacturing company.

Advanced users comfortable with higher-than-standard dosing. The epithalon cycle (100mg total) is double the standard Khavinson protocol (50mg). The BPC-157 monthly pulse (10mg) is 20x the typical daily dose. Prior experience with both peptides individually is recommended before combining them at these levels. Tremblay has commercial interest as the owner of CanLab (peptide manufacturer), which is worth factoring into your evaluation.

Epithalon was developed by Khavinson, whose published data shows telomerase activation in human cell cultures (Khavinson, PMID 14523363). Standard Khavinson dosing is 5-10mg daily for 5-10 days (50mg max per cycle). Tremblay's 100mg cycle exceeds this by 2x, based on his manufacturing and clinical experience. BPC-157 has 100+ preclinical studies on tissue repair (Sikiric et al., PMID 9073154). The 10mg single-dose approach has no published research behind it. Tremblay discussed his rationale on Ben Greenfield Life, citing 30+ years of peptide synthesis experience.